Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
4.070
+0.090 (2.26%)
May 14, 2026, 4:00 PM EDT - Market closed
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
$328,000
Profits / Employee
-$293,581
Market Cap
302.50M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 229 | 7 | 3.15% | 224 | 5 |
| Dec 31, 2024 | 222 | 1 | 0.45% | 216 | 6 |
| Dec 31, 2023 | 221 | -16 | -6.75% | 216 | 5 |
| Dec 31, 2022 | 237 | -63 | -21.00% | 231 | 6 |
| Dec 31, 2021 | 300 | 19 | 6.76% | 294 | 6 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Niagen Bioscience | 117 |
| Zentalis Pharmaceuticals | 106 |
| OmniAb | 89 |
| Armata Pharmaceuticals | 60 |
| Protara Therapeutics | 46 |
| Inhibikase Therapeutics | 35 |
| Eledon Pharmaceuticals | 33 |
CLLS News
- 2 days ago - Cellectis (CLLS) Announces Clinical Trial Presentations at EHA Congress - GuruFocus
- 2 days ago - Cellectis to present clinical data on lasme-cel, eti-cel at EHA Congress - TheFly
- 2 days ago - Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - GlobeNewsWire
- 2 days ago - Cellectis (CLLS) Reports Strong Cash Position for Future Operations - GuruFocus
- 2 days ago - Cellectis (CLLS) Reports Q1 Revenue and Highlights Future Developments - GuruFocus
- 3 days ago - Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year - TheFly
- 3 days ago - Cellectis sees cash runway into 4Q27 - TheFly
- 3 days ago - Cellectis Reports Financial Results for the First Quarter 2026 - GlobeNewsWire